- Home
- BBIO
as 05-30-2025 11:31am EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 6.7B | IPO Year: | 2019 |
| Target Price: | $57.09 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $39.54 | Next Earning Date: | 04-29-2025 |
| Revenue: | $127,415,000 | Revenue Growth: | -41.71% |
| Revenue Growth (this year): | 89.1% | Revenue Growth (next year): | 57.07% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | May 12 '25 | Sell | $34.20 | 6,000,000 | $205,200,000.00 | 13,260,971 | |
| Lo Andrew | BBIO | Director | May 2 '25 | Sell | $38.50 | 100,000 | $3,849,900.00 | 105,583 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | May 2 '25 | Sell | $38.51 | 1,026 | $39,509.11 | 147,639 | |
| Kumar Neil | BBIO | Chief Executive Officer | Apr 22 '25 | Sell | $34.11 | 75,000 | $2,558,025.00 | 4,873,447 | |
| Ellis Andrea | BBIO | Director | Apr 14 '25 | Sell | $35.00 | 10,000 | $350,000.00 | 12,000 | |
| Ellis Andrea | BBIO | Director | Apr 1 '25 | Sell | $34.05 | 30,000 | $1,021,500.00 | 12,000 | |
| Kumar Neil | BBIO | Chief Executive Officer | Mar 25 '25 | Sell | $36.87 | 75,000 | $2,764,942.50 | 4,873,447 | |
| Valantine Hannah | BBIO | Director | Mar 6 '25 | Sell | $32.58 | 12,875 | $419,499.69 | 1,764 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | Mar 5 '25 | Sell | $32.96 | 6,000,000 | $197,760,000.00 | 13,260,971 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
Barrons.com
7 days ago
Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors
Insider Monkey
9 days ago
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment
Zacks
10 days ago
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
GlobeNewswire
10 days ago
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
MT Newswires
11 days ago
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis
GlobeNewswire
11 days ago
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
GlobeNewswire
16 days ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Clinical Trials Arena
16 days ago
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.